Skip to main content
. 2017 Mar 21;8(22):35946–35961. doi: 10.18632/oncotarget.16412

Figure 8. Reparixin inhibits xenograft growth of TC cells in nude mice.

Figure 8

(A) Growth curves of xenografts of 8505c cells stably overexpressing IL-8 (clone 19) or control cells (pBABE) in immunocompromised mice, treated with 30 mg/kg/die Reparixin or PBS vehicle. *P < 0.05 compared to the relative vehicle-treated group of mice. (B) IHC on excised IL-8 overexpressing or pBABE tumors treated or not with Reparixin for Ki-67+ cells, Cleaved caspase-3+ cells and CD31+ vessels (5 fields/sample). The quantification and representative photograms are shown. *p < 0.05 compared to relative vehicle-treated xenografts. (C) Effect of Docetaxel and Reparixin in 8505c pBABE (left panel) and IL-8 cl19 (right panel) xenografts. Docetaxel was injected i.p. at a dose of 5 mg/kg on days 9, 16, and 23; Reparixin was administred i.p. at 30 mg/Kg/die; combined treatment included both drugs. Control group mice received vehicle injections only. For 27 days, tumor size was monitored twice a week. *P < 0.05 compared to the relative vehicle-treated group of mice; §P < 0.05 compared to the single drug-treated group of mice.